.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XL01_SitimageneCeradenovec.SitimageneCeradenovec .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XL01_SitimageneCeradenovec.SitimageneCeradenovec| name: | SitimageneCeradenovec | |
| ATC code: | L01XL01 | |
| route: | intracerebral | |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Sitimagene ceradenovec is a replication-deficient adenoviral vector encoding the herpes simplex virus thymidine kinase (HSV-tk) gene, used in gene-directed enzyme prodrug therapy (GDEPT). It is utilized in the treatment of malignant glioma as an adjunct to surgical resection, where the HSV-tk gene renders tumor cells sensitive to ganciclovir. The drug is not widely approved and has been used investigationally in the EU under the name Cerepro.
No peer-reviewed pharmacokinetic studies exist for sitimagene ceradenovec, as it is a gene therapy vector and not a classical pharmaceutical agent. Estimates below are provided as empty according to instructions due to lack of available data.